The GYS1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the A-549 lung adenocarcinoma line. They carry a targeted disruption of the GYS1 gene, encoding glycogen synthase 1, via CRISPR/Cas9-mediated gene disruption. This heterogeneous pool of loss-of-function edits provides a robust model for studying glycogen metabolism without clonal selection bias, ideal for bulk functional analyses in a cancer cell context.
The parental A-549 cell line is a widely used in vitro model derived from a 58-year-old Caucasian male with lung adenocarcinoma. These epithelial cells harbor an activating KRAS G12S mutation and retain wild-type p53, making them representative of a subset of non-small cell lung cancers with deregulated RAS signaling. A-549 cells are valued for their ability to model alveolar type II pneumocyte biology, nutrient sensing, and metabolic adaptations characteristic of malignant cells. Their epithelial morphology and baseline metabolic profile provide a relevant background for examining the role of glycogen synthesis in tumor cell bioenergetics and stress responses.
GYS1 catalyzes the rate-limiting step in glycogen synthesis by transferring glucose from UDP-glucose to a growing glycogen chain. Its activity is tightly regulated by insulin and energy-sensing pathways. Insulin binding to INSR recruits IRS1 to activate PI3K/AKT signaling; AKT phosphorylates GSK3??, inhibiting its kinase activity and relieving GYS1 repression. In contrast, AMPK and PKA phosphorylate GYS1 to suppress glycogen synthesis under energy stress or hormonal cues. The scaffolding protein PPP1R3A directs protein phosphatase 1 to glycogen particles, counteracting inhibitory phosphorylations on GYS1. Additionally, glucose-6-phosphate functions as an allosteric activator, coupling substrate availability to enzyme activity. Glycogenin primes glycogen granule formation, while GSK3?? and AMPK directly modulate GYS1 phosphorylation status. Collectively, GYS1 integrates insulin, AMPK, and nutrient signals to govern cellular glycogen stores and energy homeostasis.
In A-549 cells, GYS1 knockout abolishes glycogen synthase activity, preventing glycogen accumulation and profoundly altering cellular energy metabolism. Given the reliance of many cancer cells on metabolic plasticity for survival under nutrient deprivation, loss of GYS1 may impair glucose buffering and reduce proliferation under hypoxic or low-glucose conditions. This model enables dissection of glycogen-dependent survival mechanisms and the interplay between glycogen metabolism, oncogenic KRAS signaling, and insulin/AMPK/mTOR networks, thereby providing insights into tumor bioenergetics and therapeutic vulnerabilities.
This knockout model is suited for diverse applications, including cancer metabolism studies, glycogen storage disease type 0 modeling, metabolic engineering, and drug target validation for type 2 diabetes and oncology. Typical assays include Western blotting to assess GYS1 depletion and signaling, glycogen quantification, glucose uptake, cell proliferation and colony formation, metabolic flux analysis, and tumor xenograft studies. For further details or technical inquiries, please contact Ascent Research.
